TTR and amyloidosis: Patisiran was the first therapy based on FDA-approved short-interfering RNA (Si-RNA) technology [22,23] and acts by reducing the production of mutant and wild-type transthyretin, thus improving the multiple clinical manifestations of hATTR amyloidosis [24].